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Background: Class III β-tubulin (TUBB3) is a prognostic marker in various tumors, but the role of TUBB3 in
advanced gastric cancer is not clearly defined. We analyzed the significance of TUBB3 expression, along with that of
excision repair cross-complementation group 1 (ERCC1) in recurrent and metastatic gastric cancer patients receiving
taxane-based first-line palliative chemotherapy.
Methods: We reviewed the cases of 146 patients with advanced gastric adenocarcinoma who received taxane-based
first-line palliative chemotherapy between 2004 and 2010 at Chonnam National University Hwasun Hospital (Gwangju,
Korea). Immunohistochemical staining for TUBB3 and ERCC1 was performed using paraffin wax-embedded tumor
tissues. We evaluated the patients’ response to chemotherapy, progression-free survival (PFS), and overall survival (OS).
Results: In total, 146 patients with advanced gastric cancer received docetaxel and cisplatin (n = 15) or paclitaxel and
cisplatin (n = 131). The median PFS was significantly shorter for patients with high-level TUBB3 expression than
for patients with low-level TUBB3 expression (3.63 vs. 6.67 months, P = 0.001). OS was not associated with
TUBB3 expression (13.1 vs. 13.1 months, P = 0.769). By multivariate analysis, only TUBB3 was related to a shorter PFS
(HR 2.74, 95% CI 1.91-3.91, P = 0.001). Patients with high-level ERCC1 expression showed a lower response rate than
patients with low-level ERCC1 expression (24 vs. 63.2%, P = 0.001); however, ERCC1 had no clinical effect on PFS or OS.
Conclusions: TUBB3 was a strong predictive marker in recurrent and metastatic gastric cancer patients receiving
taxane-based first-line palliative chemotherapy. No clinical impact of ERCC1 was evident in this setting.
Keywords: Class III β-tubulin (TUBB3), Excision repair cross-complementation group 1 (ERCC1), Taxane, Stomach
neoplasm, MetastasisBackground
Gastric cancer is one of the leading causes of cancer-related
death. Although its global incidence is declining, gastric
cancer remains highly prevalent in many Asian countries
[1,2]. Conventional treatments such as surgery, radiother-
apy, and chemotherapy play a role primarily in patients
with early-stage disease. However, they have only modest
efficacy in treating patients with recurrent or metastatic
gastric cancer [3].* Correspondence: ijchung@chonnam.ac.kr
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reproduction in any medium, provided the orMolecular and genetic alterations are complex in the
pathogenesis of gastric cancer. Many different cellular
pathways may play important roles in gastric carcinogen-
esis, and the predominant driving pathway can be difficult
to delineate [4,5]. However, recently, HER-2 overexpression
and amplification were shown to be effective predictive
markers in gastric cancer with the release of promising
results from the Trastuzumab for Gastric Cancer trial [6].
Predictive biomarkers indicate the likely benefit of treat-
ment, whereas prognostic biomarkers are associated with
survival that is independent of the treatment effect.
Markers can be prognostic and/or predictive [7].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hwang et al. BMC Cancer 2013, 13:431 Page 2 of 8
http://www.biomedcentral.com/1471-2407/13/431Taxanes (docetaxel and paclitaxel) are anticancer agents
that bind to microtubules and induce hyperstabilization,
causing a cell cycle arrest and apoptosis [8,9]. They are
widely used and effective chemotherapeutic agents in ad-
vanced gastric cancer [10-16]. Class III β-tubulin (TUBB3)
has been shown to play a role in chemotherapy resistance
in various cancer types [17]. The role of TUBB3 has been
studied in non-small cell lung cancer (NSCLC), and it has
been shown to be associated with resistance to anti-
tubulin agents, including taxanes [18,19]. TUBB3 is also a
prognostic factor in NSCLC. However, the role of TUBB3
in gastric cancer has not been widely investigated, al-
though it is important in the treatment of gastric cancer
to predict chemosensitivity with the goal of improving the
response rate and overall survival (OS), and preventing
unnecessary side effects and useless treatments. Thus,
TUBB3 may provide important information for planning
gastric cancer treatment regimens.
Excision repair cross-complementation group 1 (ERCC1)
has also been investigated in NSCLC. It is a prognostic
marker for resected NSCLC and a predictor of a lack of
benefit from platinum-based adjuvant chemotherapy
[20,21]. The role of ERCC1 in advanced gastric cancer has
not been extensively evaluated. There is a report suggesting
that high levels of ERCC1 expression in gastric cancer may
be associated with poor survival and a lack of response to
cisplatin [22]; however, its role remains controversial.
In this study, we analyzed the significance of TUBB3
and ERCC1 in recurrent and metastatic gastric cancer
patients receiving first-line palliative chemotherapy. The
chemotherapeutic regimens used consisted of taxane
(paclitaxel or docetaxel) and cisplatin. The objective of
this study was to determine the role of TUBB3 and




We reviewed the cases of 146 patients with unresectable
recurrent or metastatic gastric adenocarcinoma who were
treated with taxane-based first-line palliative chemotherapy
between January 2004 and December 2010 at Chonnam
National University Hwasun Hospital (Gwangju, Korea),
and whose paraffin wax-embedded tumor tissue at diagno-
sis and medical records were available (Figure 1). We used
endoscopic biopsy specimens in cases of initially metastatic
patients, whereas resected samples were used in cases of
recurrence after curative resection. Patients were staged
using a combination of endoscopy, computed tomographic
scans of the chest and abdomen, and positron emission
tomography or bone scans, when clinically indicated. Data
regarding patient demographics, chemotherapeutic regi-
men, chemotherapy response, progression-free survival
(PFS), and OS were obtained by medical record review.Chemotherapy
The chemotherapy regimens consisted of cycles of
taxane (paclitaxel or docetaxel) and cisplatin. In total, 131
patients received PC chemotherapy, consisting of pac-
litaxel (175 mg/m2 of Taxol; Bristol-Myers Squibb
Pharmaceuticals, New York, NY, USA) and cisplatin
(75 mg/m2) on day 1, while 15 patients received DC
chemotherapy, consisting of docetaxel (75 mg/m2 of
Taxotere; Sanofi Aventis, Paris, France) and cisplatin
(75 mg/m2) on day 1. Each regimen was repeated every
3 weeks.
The schedule was repeated until the occurrence of
disease progression, lack of clinical benefit, unaccept-
able toxicity, or patient refusal. Hematological and
non-hematological adverse events were evaluated. The
management of adverse events and subsequent dose
reduction of chemotherapeutic agents was carried out
in a conventional manner. A total of 92 patients received
full-dose intense chemotherapy, while 54 patients required
a modification of the dose or chemotherapy interval.
Response evaluation
The clinical tumor response was assessed radiologically
by computed tomography after every two courses of
chemotherapy, according to the Response Evaluation
Criteria in Solid Tumors (ver. 1.0) [23]. PFS was defined
as the period from the start of chemotherapy to docu-
mentation of disease progression or death from any
cause, whichever occurred first. If neither event had
occurred at the time of the last record, the patient was
censored at that time. OS was calculated from the start
of chemotherapy to death from any cause.
This study protocol was reviewed and approved by
the Institutional Review Board of Chonnam National
University Medical School Research Institution. Written
informed consent was obtained from all patients prior to
their inclusion in the study.
Immunohistochemical staining for TUBB3 and ERCC1
Immunohistochemical staining for TUBB3 and ERCC1
was performed on paraffin wax-embedded tissue sections.
The sections (4 μm) were deparaffinized, rehydrated,
rinsed with distilled water, and washed with Tris-buffered
saline. Antigen retrieval was performed using a heat-
induced epitope retrieval method. Avidin-biotin peroxid-
ase complexes were identified using diaminobenzidine
(Sigma-Aldrich, St. Louis, MO, USA) as the chromogen
with a streptavidin-horseradish peroxidase detection
system (Ventana; Biotek Solutions, Tucson, AZ, USA).
A rabbit monoclonal antibody against TUBB3 (clone
EP1331Y, 1:250; Abcam PLC, Cambridge, UK) and a
mouse monoclonal antibody against ERCC1 (clone 8 F1,
1:100; Abcam PLC) were used as primary antibodies.
Antibody use and all subsequent steps were performed
A total of 779 patients with gastric cancer were
screened (1/1/2004-12/31/2010)
A total of 573 cases were excluded due to other first-
line chemotherapy (e.g., oxaliplatin, irinotecan, or 
TS-1) or synchronous cancers.
A total of 206 eligible 
cases were screened.
A total of 146 patients were selected.
A total of 27 patients were lost 
to follow-up; 33 tissues were 
unavailable.
Figure 1 Enrollment.
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tochemical staining was repeated for samples giving
inconsistent results. H-scores ≥ 4 (median value for both
TUBB3 and ERCC1) for TUBB3 and ERCC1 were classi-
fied as high-level expression.
Microscopic analysis
All of the immunostaining results were assessed by two
independent pathologists (JHL and KHL) who had no
knowledge of the patients’ clinical data. The TUBB3 and
ERCC1 staining intensities (cytoplasmic staining for
TUBB3 and nuclear staining for ERCC1) were graded on
a scale of 0 to 2 (0 = none, 1 = weak, and 2 = strong),
using adjacent non-malignant cells for reference. The
percentage of positive tumor cells was evaluated and a
proportion score was attributed to TUBB3 and ERCC1
(0 if 0%, 1 if 1-10%, 2 if 11-50%, and 3 if 51-100%). This
proportion score was multiplied by the staining intensity
to obtain a final semi-quantitative H-score for TUBB3
and ERCC1 [24].
Statistical analysis
Variables for inclusion in the model were age, sex, tumor
location, histological grade, Lauren’s classification, disease
status, liver metastasis, bone metastasis, peritoneal metasta-
sis, chemotherapy response, chemotherapeutic regimen,
number of involved organs, TUBB3 expression, and ERCC1
expression. A comparison of clinicopathological parameters
was evaluated with Pearson’s chi-squared test or Fisher’s
exact test, as appropriate. Odds ratios (ORs) with confi-
dence intervals (CIs) for categorical outcomes were
calculated using a binary logistic regression model. TheKaplan-Meier method was used to construct PFS curves.
Differences between survival curves were tested using the
log-rank test. To identify independent factors significantly
related to patient prognosis, we used Cox proportional
hazard analysis with a step-wise forward procedure.
All statistical tests were two sided, and P < 0.05 were
considered to indicate statistical significance. All analyses




The demographic details of the patients are presented in
Table 1. In total, 146 patients received taxane-based
first-line palliative chemotherapy. The median age of the
patients was 56 (range, 19–75) years; the study popula-
tion included 104 males (71.2%) and 42 females (28.8%).
Regarding the histopathological classification, 86 (59.0%)
were intestinal, 43 (29.4%) were diffuse, and 17 (11.6%)
were mixed-type. In total, 90 patients (61.6%) had initially
metastatic disease, and 56 patients (38.4%) had recurrent
disease after curative resections. In total, 766 treatment
cycles were delivered, with a median number of five cycles
per patient (range, 1-15). A total of 9 patients (6.2%) received
more than ten cycles of chemotherapy.
TUBB3 and ERCC1 expression
Of the 146 archival specimens, 77 (52.7%) and 78 (53.4%)
showed high-level expression of TUBB3 and ERCC1, re-
spectively. The immunostaining patterns for TUBB3 were
cytoplasmic, whereas the ERCC1 expression patterns in
the tumor cells were nuclear (Figure 2) The expression






H-score 1-3 H-score 4-6
Age
< 56 32 (44.4) 40 (55.6) 0.105
≥ 56 37 (50.0) 37 (50.0)
Sex
Male 49 (47.1) 55 (52.9) 1
Female 20 (47.6) 22 (52.4)
Location
GEJ-cardia 9 (56.3) 7 (43.8) 0.8
Body 42 (45.7) 50 (54.3)
Antrum 18 (47.4) 20 (52.6)
Differentiation
Well, moderately 15 (41.7) 21 (58.3) 0.45
Poorly, signet ring cell 54 (49.1) 56 (509)
Lauren classification
Intestinal 41 (47.7) 45 (52.3) 0.211
Diffuse 17( 39.5) 26 (60.5)
Mixed 11 (64.7) 6 (35.3)
Disease status
Initial metastasis 41 (45.6) 49 (54.4) 0.614
Recurrence after
curative resection
28 (50.0) 28 (50.0)
Metastatic site
Liver
Yes 20 (48.8) 21 (51.2) 0.855
No 49 (46.7) 56 (53.3)
Peritoneum
Yes 35 (53.0) 31 (47.0) 0.245
No 34 (42.5) 46 (57.5)
Bone
Yes 5 (50.0) 5 (50.0) 1
No 64 (47.1) 72 (52.9)
Chemotherapy response
CR + PR 34 (54.8) 28 (45.2) 0.133





58 (44.3) 73 (55.7) 0.053
Docetaxel and
cisplatin
11 (73.3) 4 (26.7)
No. of involved organs
1 41 (41.8) 57 (58.2) 0.107
2 25 (61.0) 16 (39.0)
≥ 3 3 (42.9) 4 (57.1)
Table 1 Patient characteristics (Continued)
ERCC1 H-score
1-3 36 (52.9) 32 (47.1) 0.245
4-6 33 (42.3) 45 (57.7)
GEJ, gastrointestinal junction; CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease; TUBB3, class III β-tubulin; ERCC1,
excision repair cross-complementation group 1.
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other (P = 0.245).
Correlations between the expression of TUBB3 and ERCC1
and clinicopathological parameters
No clinical parameter examined was associated with
TUBB3 expression. ERCC1 expression was only associated
with response rate. The response rate (CR + PR) to chemo-
therapy was 44%. Patients with high-level ERCC1 expres-
sion showed significantly lower response rates than
patients with low-level ERCC1 expression (24.4 vs. 63.2%,
P = 0.001). High-level TUBB3 expression was associated
with a lower response rate, but not significantly so (36.4 vs.
49.3%, P = 0.115). By multivariate analysis, considering
chemotherapy response, ERCC1 was a negative predictive
marker for response rate (adjusted OR 5.038, 95% CI 2.44-
10.37, P = 0.001).
Expression of TUBB3 and ERCC1 and clinical outcome
The median follow-up duration (from the first visit to
death or the date of last follow-up) was 23.7 months
(range, 4.9-75.4 months). Six patients were alive at the
time of analysis. The median PFS and OS of the patients
were 4.4 months (95% CI 3.74-5.11) and 13.1 months
(95% CI 10.5-15.6), respectively. Univariate analyses of
the clinicopathological parameters and PFS and OS
are shown in Table 2. In the univariate analysis, high-level
TUBB3 expression was significantly associated with a
shorter PFS (median 3.6 vs. 6.7 months; P = 0.001; Table 2
and Figure 3). OS was not associated with TUBB3 expres-
sion status (13.1 vs. 13.1 months; P = 0.769). ERCC1
showed no clinical effect on PFS or OS. PFS was 3.8 months
in the high-level ERCC1 expression group and 5.2 months
in the low-level expression group (P = 0.28). OS was in
12.7 months in the high-level ERCC1 expression group and
13.5 months in the low-level expression group (P = 0.916).
In the multivariate analysis, high-level TUBB3 expression
was an independent prognostic factor for poor PFS (HR
2.74, 95% CI 1.91-3.91, P = 0.001). No clinical parameter
examined was significantly associated with PFS or OS.
Neither TUBB3 nor ERCC1 predicted OS.
Discussion
Tubulin-binding agents are an important class of com-
pounds in the field of anti-neoplastic chemotherapy,
with broad activity in both solid tumors and hematological
Figure 2 Representative examples of class III β-tubulin (TUBB3) and excision repair cross-complementation group 1 (ERCC1)
immunostaining (×200). (A) TUBB3 H-score < 4. (B) TUBB3 H-score = 6. (C) ERCC1 H-score < 4. (D) ERCC1 H-score = 6.
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http://www.biomedcentral.com/1471-2407/13/431malignancies [14,25]. These agents block cell division by
inhibiting the mitotic spindle. Taxanes (paclitaxel and
docetaxel) promote the polymerization of purified tubulin
in vitro at high concentrations and enhance the fraction of
polymerized tubulin in cells. Thus, they have been referred
to as microtubule-stabilizing agents.
Several mechanisms have been reported to be in-
volved in resistance to tubulin-binding agents. One is
TUBB3 overexpression. Many preclinical studies have
shown that high levels of TUBB3 expression are asso-
ciated with taxane resistance in various human cancer
cell lines, including lung, ovary, prostate, breast, and
pancreas [26-29].
In NSCLC, TUBB3 is considered to be a predictive
marker for chemotherapy and a prognostic marker at
the same time. That is, high-level expression of TUBB3
is associated with a poorer response to chemotherapy,
faster disease progression, and worse survival in NSCLC
patients [18,19,30]. Several clinical studies have assessed
the prognostic or predictive value of TUBB3 expression in
patients with ovarian, cervical, or breast cancer. Most of
these studies have shown that TUBB3 expression is asso-
ciated with resistance to tubulin binding agents, a poor
prognosis, or both [17]. Koh et al. [31] also reported that
TUBB3-positive patients showed lower response rates,
and that the PFS and OS times were shorter in patients
with head and neck squamous cell carcinoma receiving
induction chemotherapy.Taxanes are widely used in gastric cancer, and the
identification of predictive markers for specific drugs
would be of value in tailoring therapy to the specific
profile of individual patients and tumors. A small cohort
study of advanced gastric cancer patients who were
receiving preoperative docetaxel-based chemotherapy
showed a correlation between TUBB3 expression and a
poor response to chemotherapy [32]. Lu et al. [33] ana-
lyzed TUBB3 mRNA expression (as determined by real-
time quantitative polymerase chain reaction) in patients
with advanced gastric cancer receiving first-line paclitaxel
plus capecitabine chemotherapy. They demonstrated that
high-level TUBB3 expression was significantly associated
with a lower response rate and shorter PFS and OS.
In this study, high-level expression of TUBB3 was asso-
ciated with a shorter PFS and a tendency to have a re-
duced response to chemotherapy, but was not associated
with OS in recurrent or metastatic gastric cancer patients
receiving taxane-based first-line palliative chemotherapy.
OS was affected by many clinical factors, including
performance status, second-line chemotherapy, and co-
morbidities, in patients with advanced gastric cancer
receiving palliative chemotherapy [34]. OS may have
been affected by the same clinical factors in this study.
ERCC1 is currently under investigation in gastric cancer,
but the influence of ERCC1 expression remains controver-
sial. Several recent reports demonstrated that high-level ex-
pression of ERCC1 was correlated with platinum resistance







< 56 4.07 (3.27-4.87) 0.937 12.73 (9.46-15.99) 0.453
≥ 56 4.70 (3.35-6.04) 13.10 (10.10-16.09)
Sex
Male 4.27 (3.49-5.04) 0.915 12.10 (10.43-13.76) 0.072
Female 4.43 (2.02-6.83) 15.37 (11.48-19.25)
Location
GEJ-cardia 3.83 (1.16-6.49) 0.926 14.03 (4.50-23.55) 0.903
Body 4.7 (3.95-5.44) 12.37 (9.17-15.56)




3.83 (3.49-4.16) 0.530 12.10 (7.79-16.40) 0.200
Poorly, signet ring
cell type
4.67 (3.77-5.56) 13.13 (10.19-16.06)
Lauren classification
Intestinal 4.20 (3.29-5.10) 0.479 13.10 (9.95-16.24) 0.626
Diffuse 4.27 (2.85-5.68) 13.13 (9.62-16.63)




4.20 (3.13-5.26) 0.714 12.10 (9.69-14.50) 0.962
Initial metastasis 4.43 (3.36-5.49) 14.17 (11.10-17.23)
Liver metastasis
Yes 4.70 (2.89-6.50) 0.537 14.03 (9.13-18.9) 0.586
No 4.27 (3.49-5.04) 13.10 (10.06-16.14)
Bone metastasis
Yes 4.70 (0.82-8.57) 0.368 9.77 (4.92-14.62) 0.685
No 4.27 (3.53-5.00) 13.13 (10.76-15.49)
Peritoneal metastasis
Yes 4.57 (2.97-6.16) 0.249 12.73 (9.04-16.41) 0.887
No 3.97 (3.15-4.78) 13.10 (9.81-16.38)
Chemotherapy
response
CR, PR 4.73 (3.12-6.33) 0.341 11.43 (8.06-14.80) 0.192
SD, PD 3.97 (3.16-4.77) 15.03 (12.33-17.72)
Chemotherapeutic
regimen
Paclitaxel/cisplatin 4.07 (3.52-4.61) 0.224 12.37 (10.23-14.50) 0.221
Docetaxel/cisplatin 6.50 (5.71-7.28) 17.87 (14.42-21.31)
No. of involved organs
1 3.97 (3.17-4.76) 0.220 12.10 (9.15-15.04) 0.570
2 4.73 (2.76-6.70) 15.13 (10.11-20.14)
≥ 3 7.07 (0.00-16.05) 12.40 (9.91-14.88)




3.63 (3.37-3.88) 0.001 13.13 (9.88-16.37) 0.769
Low-level
expression




3.77 (3.54-3.99) 0.280 12.70 (9.45-15.94) 0.916
Low-level
expression
5.23 (3.74-6.71) 13.53 (10.10-16.95)
mPFS, median progression-free survival; mOS, median overall survival;
GEJ, gastrointestinal junction; CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease; TUBB3, class III β-tubulin;
ERCC1, excision repair cross-complementation group 1.
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[35,36]. In contrast, other studies have demonstrated that
low-level ERCC1 expression was correlated with poor sur-
vival or showed no correlation with survival [37,38]. These
seemingly conflicting results may be related to biological
variation in the tumors analyzed, to variation in the chemo-
therapeutic protocols, and/or to the different techniques
used to assess ERCC1 expression.
In this study, ERCC1 had no effect on PFS or OS,
and was only associated with the clinical response to
chemotherapy. There is a clinical study showing that
paclitaxel may help alleviate ERCC1-related platinum
resistance in ovarian cancer [39]. Cisplatin monotherapy
is not commonly used; taxane monotherapy is used to
treat advanced gastric cancer [40,41]. Thus, paclitaxel
might play a greater role than cisplatin in patients
with advanced gastric cancer treated with taxane-cisplatin
chemotherapy.Figure 3 PFS in patients with advanced gastric cancer according
to the expression of class III β-tubulin (TUBB3) (high- vs. low-level
expression; 3.63 vs. 6.67 months, P = 0.001) (solid line, low-level
TUBB3 expression; dotted line, high-level TUBB3 expression).
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http://www.biomedcentral.com/1471-2407/13/431Despite demonstrating the predictive significance of
TUBB3 expression, the present study has several poten-
tial limitations. First, it was a retrospective analysis from
a single institution. Therefore, the chemotherapy dose
and schedule might be different from patient to patient
according to individual patient organ function, tolerabil-
ity, and toxicity profiles. Second, this study included a
somewhat heterogeneous patient population. Among
146 patients, 90 initially presented with metastatic disease,
whereas 56 had recurrent disease after curative resection.
Third, TUBB3 expression did not correlate with other
clinical parameters such as histological grade or Lauren
classification. Finally, it is possible that the immunohisto-
chemical staining results of the pretreatment endoscopic
biopsy specimens or resected samples did not correlate
with those of the entire primary tumor or metastatic
tissue.
Additional prospective, randomized controlled trials
are needed to identify the true significance of TUBB3
and ERCC1 in the prognosis of gastric cancer. Random-
ized clinical trials may also account for confounding
variables such as patient performance status.
Conclusions
In conclusion, in advanced gastric cancer, TUBB3 was a
predictive marker for taxane-cisplatin chemotherapy.
ERCC1 was not associated with PFS or OS. Immunohisto-
chemical analysis of pre-treatment biopsies for TUBB3 may
provide valuable information to oncologists in selecting
appropriate chemotherapeutic regimens.
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